company Nucor Pharmaceutical will invest 6.1 million euros in a project environmental impact reduction Connected to your production process Urquima Chemical Plant, is located in Sant Fost de Campsentelles (Barcelona). the firm that made Investment Fund MCH Private Equity (70% of the capital) and a private group of Catalan investors, in 2021, through the purchase of the B2B business of the pharmaceutical company Uriach – in the operation of By-productIt will finance environmental measures with European Next Generation Funds. The funding provided includes a non-refundable grant of 617,000 Euros and a loan of 4.3 million Euros.
Under the objectives defined by Urkima, within the framework of its Environmental Strategy for 2022-2025, the resources obtained will be used to: two lines of action To reduce the impact of the plant’s production process: Reduction in the emission of polluting gases why reduction in the amount of waste water, In this sense, through a variety of actions, Nucor will reduce emissions of volatile organic compounds (VOCs) released into the atmosphere by more than 60% to minimal levels – well below established legal limits. Similarly, the company will reduce the amount of wastewater by 80% and reuse the clean water obtained after the evaporation process.
With regard to the reduction of gases, Urquima considers two actions that would mean a significant environmental improvement and a positive impact on air quality: the adaptation of air purification systems, which eliminate polluting particles from gaseous emissions, and regenerative thermal oxidation. Installation of equipment that primarily converts chemical substances containing carbon into carbon dioxide and water. In addition, Nucor will install a wastewater evaporation system that will treat liquids produced during the processes and generate two streams: one high-quality water that can be reused and the other as concentrated wastewater.
The investment Nucor will make in Urquima will also help create jobs at the factory. since its constitution and has been taking advantage of technical Info D Uriach, the pharmaceutical company focused on the manufacture of Generic drugs, licensing, development of new innovative molecules and production for third parties, with distribution in more than 100 countries, and hopes to internationalize it in markets such as China, the United States or Japan. Among its most commercial products is the antihistamine rupatadineWhich has been introduced in major markets such as Japan, South Korea or Canada.
The company, directed by David Perdigo, is one of seventeen companies that have benefited from European subsidies and received 40% of the total aid given through the ministry. Currently, the pharmaceutical company has three manufacturing plants: a fine chemicals plant (Urquima), dedicated to the production of active ingredients, and another pharmaceutical center and a plant focused on food supplements, both in Palau-Solita i Plagueman. are located. The three production centers employ over 450 people, of whom a hundred work in Urkima.
Nucor’s three main business areas are Innovative Products (new chemical entities), manufacturing for generic products and third brands (contract manufacturing), of which Euryache is. The company focuses on the worldwide sale of active ingredients (APIs) and pharmaceutical products with a broad portfolio in various specialties such as Central Nervous System, Respiratory, Dermatology, Cardiovascular and Urology.
Disinvestment of Uriyach
The MCH Fund is also a shareholder of the Catalan family business Europastry, which is closing last year’s results, an exercise in which it expected the business to grow to the 100 million euro figure. For its part, through the divestment, Uriach concludes a strategic plan launched a decade ago to focus 100% consumer health service (non-prescription products), focuses on natural products with scientific basis and promoting the internationalization of its core brands. The current turnover of the Uriach Group exceeds 200 million Euros.
The growth of Family Pharmacies, a group that dates back to 1838, has focused in recent years on the acquisition of brands positioned in European markets. An example is the purchase of Laborest, Progine and AR Fitofarma in Italy; Or Theralab, in Portugal. The most recent operation was carried out in 2021 to gain market share in Germany, Austria and Switzerland through the purchase of Sidroga.